Amicus Therapeutics Appoints Burke W. Whitman to its Board of Directors
May 13 2019 - 5:00PM
Amicus Therapeutics (Nasdaq: FOLD) today announced the election and
appointment of Burke W. Whitman to its Board of Directors,
effective at the end of this quarter. Mr. Whitman is a proven
leader of corporate and military organizations. He has served
as a corporate CEO, CFO and board member of multiple
publicly-traded and Fortune 500 healthcare service companies, as
well as the commanding general of the 4th Marine Division and the
commander of Marine Forces Reserve.
John F. Crowley, Chairman and Chief Executive
Officer of Amicus Therapeutics, Inc., stated, “On behalf of our
Board of Directors, I am pleased to announce Burke Whitman’s
appointment to the Amicus Board. Burke brings tremendous experience
in leadership, strategy, operations and organizational
effectiveness in both the military and in the healthcare fields.
His remarkable service to our nation is humbling and his extensive
high integrity executive leadership in healthcare and his boardroom
experience will add much to our mission at Amicus for patients and
for shareholders. Burke’s appointment complements our existing
strong group of directors and senior leaders as we continue to
build one of the world’s leading global biotechnology companies in
rare metabolic diseases.”
Currently a major general in the United States
Marine Corps Reserve, Mr. Whitman has held various roles of
increasing responsibility in the Marine Corps since 2008, and will
complete his uniformed service in 2019. A veteran of multiple
combat deployments, his decorations include a Defense Superior
Service Medal, two Legion of Merit Medals, a Bronze Star Medal, two
Combat Action Ribbons, and a Presidential Unit Citation.
Concurrently, since 2018 he serves as a member of the board of
directors of Omega Healthcare Investors, Inc. (NYSE: OHI).
Prior to returning to active military service in 2008, Mr. Whitman
served as the Chief Executive Officer and as a director of Health
Management Associates, Inc. (formerly NYSE: HMA), an owner and
operator of acute care hospitals, where he was named a Best CEO by
Institutional Investor magazine in 2008. From 1998 to 2005,
Mr. Whitman served as the Chief Financial Officer of Triad
Hospitals, Inc. (formerly NYSE: TRI), an owner and operator of
hospitals, where he was twice named a Best CFO by Institutional
Investor magazine.
Mr. Whitman has served on the board of directors
of the Toys for Tots Foundation as chairman of the investment
committee, and on the board of directors of the Federation of
American Hospitals as chairman of the audit committee. He is
a founder of the National Museum of the Marine Corps, and has
served on the board of advisors of Marine Corps University.
Currently he serves on the U.S. Reserve Forces Policy Board as an
advisor to the Secretary of Defense, and on the board of trustees
of the Lovett School in Atlanta. Mr. Whitman received a Master of
Business Administration from Harvard Business School, a Master of
Strategic Studies from the U.S. Army War College, and a Bachelor of
Arts from Dartmouth College.
“Amicus is at the forefront of science and
innovation, with a unique dedication to people living with rare
diseases. The Amicus focus on its mission for patients, its
remarkable commitment and vision to become one of the world’s most
significant biotechnology companies are what drew me to this
opportunity. I am thrilled to be joining the Board at such an
exciting time in the Company’s growth,” said Mr. Whitman. “I look
forward to advancing the company’s mission to develop
groundbreaking new medicines and hopefully one day cures for
life-threatening conditions.”
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated
biotechnology company focused on discovering, developing and
delivering novel high-quality medicines for people living with rare
metabolic diseases. With extraordinary patient focus, Amicus
Therapeutics is committed to advancing and expanding a robust
pipeline of cutting-edge, first- or best-in-class medicines for
rare metabolic diseases. For more information please visit the
company’s website at www.amicusrx.com, and follow on Twitter and
LinkedIn.
CONTACTS:
Investors:Amicus
TherapeuticsSara Pellegrino, IRCVice President, Investor Relations
& Corporate Communicationsspellegrino@amicusrx.com(609)
662-5044
Media:Amicus TherapeuticsMarco
Winklermwinkler@amicusrx.com(609) 662-2798
FOLD–G
Omega Healthcare Investors (NYSE:OHI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Omega Healthcare Investors (NYSE:OHI)
Historical Stock Chart
From Sep 2023 to Sep 2024